Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01350401 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma
A Phase 1 study, sponsored by Adaptimmune.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT01350401 is a Phase 1 study that was terminated before completion, run by Adaptimmune. The registered enrollment target is 4 participants.
The verdict
NCT01350401, a Phase 1 study, was terminated before completion, sponsored by Adaptimmune.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this early (phase I/II) clinical trial is to assess the effects (both good and bad) of genetically modified T cells after chemotherapy on your cancer and general health.
Interventions
- GENETIC Autologous genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2011-06-01 |
| Est. Completion | 2018-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01350401
The ClinicalTrials.gov registry entry for NCT01350401 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adaptimmune, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Autologous genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T is the first listed.
NCT01350401 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01350401 about?
NCT01350401 is a clinical study titled "Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma". The purpose of this early (phase I/II) clinical trial is to assess the effects (both good and bad) of genetically modified T cells after chemotherapy on your cancer and general health.
What is the current status of trial NCT01350401?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2011-06-01. Estimated completion is 2018-03-01.
What interventions are being tested in trial NCT01350401?
The interventions under investigation include: Autologous genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T (GENETIC).
Who is sponsoring clinical trial NCT01350401?
This trial is sponsored by Adaptimmune, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.